A high-throughput zebrafish screen identifies novel candidate treatments for kaposiform lymphangiomatosis (KLA)
Journal of Experimental Medicine · 2025
DOI: 10.1084/jem.20240513 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, 2025. Verfasst von Ivan Bassi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel. Hauptthemen laut MEDLINE: Zebrafish, High-Throughput Screening Assays, Kasabach-Merritt Syndrome, Hemangioendothelioma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: European Research Council, Orphan Disease Center, Estate of Emile Mimran.
Abstract (Originalsprache)
Kaposiform lymphangiomatosis (KLA) is a rare and aggressive disease caused by a somatic activating NRAS mutation (p.Q61R) in lymphatic endothelial cells (LECs). The development of new therapeutic avenues is hampered by the lack of animal models faithfully replicating the clinical manifestations of KLA. Here, we established a novel zebrafish model of KLA by conditionally expressing the human NRAS mutation in venous and lymphatic ECs. Mutant embryos recapitulate key clinical features of KLA, including dilated lymphatics and pericardial edema, which are reversed by trametinib, a MEK inhibitor used in KLA treatment. Leveraging this model in combination with an AI-based high-throughput drug screening platform, we identify cabozantinib, a tyrosine kinase inhibitor, and GSK690693, a competitive pan-Akt kinase inhibitor, as promising candidates for treating KLA. Notably, both drugs normalized sprouting and migration of cultured LECs from a KLA patient. Overall, our novel zebrafish model provides a powerful platform to dissect KLA pathogenesis and identify new therapeutic avenues.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel.
- Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv, Israel.
- Department of Dermatology, Sheba Medical Center, Ramat Gan, Israel.
- Department of Pathology, Sheba Medical Center, Ramat Gan, Israel.
- IDEA Bio-Medical Ltd. , Rehovot, Israel.
- The Maurice and Vivienne Wohl Institute for Drug Discovery, The Nancy and Stephen Grand Israel National Center for Personalized Medicine (INCPM), Weizmann Institute of Science , Rehovot, Israel.
ORCID-Profile: Ivan Bassi, Amani Jabali, Lotan Levin, Giuseppina Lambiase, Noga Moshe, Naama Farag, Yaara Tevet, Gal Perlmoter, Shany Egozi, Gil S Leichner, Polina Geva, Aviv Barzilai, Camila Avivi, Jonathan Long, Jason J Otterstrom, Yael Paran, Haim Barr, Karina Yaniv, Shoshana Greenberger
Förderung
- European Research Council
- Orphan Disease Center
- Estate of Emile Mimran
- Maurice and Vivienne Wohl Biology Endowment
- Brenden-Mann Women's Innovation Impact Fund
- Lymphatic Malformation Institute
- Sheba Medical Center
- Weizmann Institute of Science
Zitieren
APA
Bassi, I., Jabali, A., Levin, L., Lambiase, G., Moshe, N., Farag, N., Tevet, Y., Perlmoter, G., Egozi, S., Leichner, G. S., Geva, P., Barzilai, A., Avivi, C., Long, J., Otterstrom, J. J., Paran, Y., Barr, H., Yaniv, K., & Greenberger, S. (2025). A high-throughput zebrafish screen identifies novel candidate treatments for kaposiform lymphangiomatosis (KLA). Journal of Experimental Medicine. https://doi.org/10.1084/jem.20240513
Vancouver
Bassi I, Jabali A, Levin L, Lambiase G, Moshe N, Farag N, et al. A high-throughput zebrafish screen identifies novel candidate treatments for kaposiform lymphangiomatosis (KLA). Journal of Experimental Medicine. 2025. doi:10.1084/jem.20240513
BibTeX
@article{Bassi2025,
author = {Bassi, Ivan and Jabali, Amani and Levin, Lotan and Lambiase, Giuseppina and Moshe, Noga and Farag, Naama and Tevet, Yaara and Perlmoter, Gal and Egozi, Shany and Leichner, Gil S and Geva, Polina and Barzilai, Aviv and Avivi, Camila and Long, Jonathan and Otterstrom, Jason J and Paran, Yael and Barr, Haim and Yaniv, Karina and Greenberger, Shoshana},
title = {A high-throughput zebrafish screen identifies novel candidate treatments for kaposiform lymphangiomatosis (KLA)},
journal = {Journal of Experimental Medicine},
year = {2025},
doi = {10.1084/jem.20240513}
}
EUVIMED